Pharmaceutical, bio pharmaceutical and small-molecule Active Pharmaceutical Ingredients (API) are the lifeline of process industry. New processes are developed each day, and the stringent process requirements of this industry are always challenging. The challenges are regulatory, environmental, and sometimes economic constraints laid by the process engineers.

API Pharmaceutical

Few applications where Diva Envitec assists are:

Diva Envitec Pvt Ltd has a wide range of products to offer to this industry segment. We help customers from initial R&D through all stages of product development and process optimisation. Our Lab and Pilot plants are suitable to carry out tests at customer sites for data generation and scale up. From input ingredient filtration, product filtration, catalyst recovery, solvent recovery to effluent treatment, we help our customers decide the right products, processes and technologies.

Some benefits our customers acquire from us are:

  • Meeting regulatory compliance
  • Meeting GMP standards
  • Process optimisation and improvement
  • New unit operations
  • Consistent quality products

The Indian pharmaceutical industry accounts for 9% of Global pharmaceutical production. Low cost of skilled manpower and innovation are some of the main factors supporting this growth. India is the third largest active pharmaceutical ingredient (API) market in the Asia-Pacific region and China is its main competitor. India has been complying with International standards and regulations.
By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and sixth largest market globally in absolute size. India’s cost of production is significantly lower than that of the US and almost half of that of Europe. It gives a competitive edge to India over others.
India’s biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry and bioinformatics is expected grow at an average growth rate of around 30 per cent a year and reach US$ 100 billion by 2025. Biopharma, comprising vaccines, therapeutics and diagnostics, is the largest sub-sector contributing nearly 62 per cent of the total revenues at Rs 12,600 crore (US$ 1.89 billion). (Source)